Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
110 hedge funds and large institutions have $854M invested in Revance Therapeutics, Inc. in 2018 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 33 increasing their positions, 29 reducing their positions, and 13 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 29
7% more call options, than puts
Call options by funds: $2.08M | Put options by funds: $1.94M
0% more funds holding
Funds holding: 110 → 110 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
11% less capital invested
Capital invested by funds: $957M → $854M (-$103M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$14.1M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$11.9M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$9.3M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$8.84M |
| 5 |
BlackRock
New York
|
+$7.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$29.8M |
| 2 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$16M |
| 3 |
Millennium Management
New York
|
-$12.3M |
| 4 |
O
OppenheimerFunds
New York
|
-$6.93M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$5.71M |
RVNC Hedge Fund Activity: Q3 2018 in Review
110 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2018, worth a combined $854M — down 11% from $957M a quarter earlier.
Fund positioning in RVNC was balanced in Q3 2018: 13 funds opened new positions, 13 closed out, 33 added to existing stakes and 29 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $14.1M. The largest seller was Jennison Associates, cutting an estimated $29.8M.
- 110 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $854M of Revance Therapeutics, Inc. stock for Q3 2018, down 11% quarter-over-quarter.
- 13 funds opened new Revance Therapeutics, Inc. positions in Q3 2018 and 13 closed out, a net change of 0 holders.
- The largest Revance Therapeutics, Inc. buyer in Q3 2018 was Bank of New York Mellon, an estimated $14.1M added.
- The largest Revance Therapeutics, Inc. seller in Q3 2018 was Jennison Associates, an estimated $29.8M sold.
Based on aggregated 13F filings for Q3 2018.